Cycle Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

$25M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Cycle Pharmaceuticals's estimated annual revenue is currently $20.7M per year.(i)
  • Cycle Pharmaceuticals's estimated revenue per employee is $201,000
  • Cycle Pharmaceuticals's total funding is $25M.

Employee Data

  • Cycle Pharmaceuticals has 103 Employees.(i)
  • Cycle Pharmaceuticals grew their employee count by 26% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.6M237-4%N/AN/A
#3
$22.3M11152%N/AN/A
#4
$23.9M1198%$113MN/A
#5
$0.3M30%N/AN/A
#6
$11.9M5923%N/AN/A
#7
$1.8M367-4%$538MN/A
#8
$48.6M24221%N/AN/A
#9
$21.4M130-13%$525.5MN/A
#10
$11.6M901%$506.4MN/A
Add Company

Innovation. Transformation. Treatment, reimagined. We reimagine how orphan drugs can benefit patients with rare diseases, to make their lives easier and improve their quality of life at every stage. By optimising and enhancing treatments, improving efficacy, identifying new indications for drugs, and reintroducing products to the market, we give patients the options they need. Cycle has three core areas of pharmaceutical development: improving drugs ᅢᄁ¬ツᆲ¬タワ optimising an existing drug; repurposing drugs ᅢᄁ¬ツᆲ¬タワ creating a new indication for an already existing drug; and generics ᅢᄁ¬ツᆲ¬タワ reinstating generic drugs, previously available in the market. These three areas of focus are underpinned by formulation technology ᅢᄁ¬ツᆲ¬タワ creating new drug delivery technologies to improve the efficacy and effectiveness of drugs, allowing us to give patients greater freedom and choice.

keywords:N/A

$25M

Total Funding

103

Number of Employees

$20.7M

Revenue (est)

26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cycle Pharmaceuticals News

2022-04-20 - Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress

Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted ... these symptoms toward the end of their treatment cycle.

2022-04-17 - The Zacks Analyst Blog Highlights UnitedHealth Group, Danaher, Wells Fargo, Vertex Pharmaceuticals and Canadian Pacific Railway

WFC, Vertex Pharmaceuticals Inc. VRTX and Canadian Pacific Railway Limited ... The sampe of results at this stage of the reporting cycle is...

2022-04-17 - Nitisinone Market Size and Growth 2022-2029| Key Players – Sobi ...

The major players covered in Nitisinone Markets: Sobi; Cycle Pharmaceuticals. Nitisinone Market Breakdown by Type: Orfadin; NITYR. Nitisinone...

2020-09-08 - Cycle Pharmaceuticals secures $25 million debt financing

Cycle Pharmaceuticals secures $25 million debt financing 08-09-2020 Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, announced that it has executed a definitive agreement for a $25 millio ...

2020-09-08 - Cycle Pharmaceuticals secures $25 million debt financing

Cycle Pharmaceuticals secures $25 million debt financing 08-09-2020 Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, announced that it has executed a definitive agreement for a $25 millio ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.5M1035%N/A
#2
$33.6M104N/AN/A
#3
$14.6M10449%N/A
#4
$16.1M1043%N/A
#5
$10.5M1052%N/A